Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3978577 | Bulletin du Cancer | 2013 | 14 Pages |
Abstract
Germ-cell tumours (GCTs) are the most common type of cancer in young men. Since the late 1970s, disseminated GCT have been a paradigm for curable metastatic cancer and metastatic GCTs are highly curable with cisplatin-based chemotherapy followed by surgical resection of residual masses. Patients' prognosis is currently assessed using the International Germ-Cell Consensus Classification (IGCCC) and used to adapt the burden of chemotherapy. Approximately 20% of patients still do not achieve cure after first-line cisplatin-based chemotherapy, and need salvage chemotherapy (high dose or standard dose chemotherapy). Clinical stage I testicular cancer is the most common presentation and different strategies are proposed: adjuvant therapies, surgery or surveillance. During the last three decades, clinical trials and strong international collaborations lead to the development of a consensus in the management of GCTs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jean-Pierre Droz, Helen Boyle, Stéphane Culine, Karim Fizazi, Aude Fléchon, Christophe Massard,